RT Journal Article SR Electronic T1 Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping JF RMD Open JO RMD Open FD EULAR SP e002025 DO 10.1136/rmdopen-2021-002025 VO 7 IS 3 A1 Eefje Martine van Helvoort A1 Paco M J Welsing A1 Mylène P Jansen A1 Willem Paul Gielis A1 Marieke Loef A1 Margreet Kloppenburg A1 Francisco Blanco A1 Ida K Haugen A1 Francis Berenbaum A1 Anne-C Bay-Jensen A1 Christoph Ladel A1 Agnes Lalande A1 Jonathan Larkin A1 John Loughlin A1 Ali Mobasheri A1 Harrie Weinans A1 Floris Lafeber A1 Niels Eijkelkamp A1 Simon Mastbergen YR 2021 UL http://rmdopen.bmj.com/content/7/3/e002025.abstract AB Objectives Osteoarthritis (OA) patients with a neuropathic pain (NP) component may represent a specific phenotype. This study compares joint damage, pain and functional disability between knee OA patients with a likely NP component, and those without a likely NP component.Methods Baseline data from the Innovative Medicines Initiative Applied Public-Private Research enabling OsteoArthritis Clinical Headway knee OA cohort study were used. Patients with a painDETECT score ≥19 (with likely NP component, n=24) were matched on a 1:2 ratio to patients with a painDETECT score ≤12 (without likely NP component), and similar knee and general pain (Knee Injury and Osteoarthritis Outcome Score pain and Short Form 36 pain). Pain, physical function and radiographic joint damage of multiple joints were determined and compared between OA patients with and without a likely NP component.Results OA patients with painDETECT scores ≥19 had statistically significant less radiographic joint damage (p≤0.04 for Knee Images Digital Analysis parameters and Kellgren and Lawrence grade), but an impaired physical function (p<0.003 for all tests) compared with patients with a painDETECT score ≤12. In addition, more severe pain was found in joints other than the index knee (p≤0.001 for hips and hands), while joint damage throughout the body was not different.Conclusions OA patients with a likely NP component, as determined with the painDETECT questionnaire, may represent a specific OA phenotype, where local and overall joint damage is not the main cause of pain and disability. Patients with this NP component will likely not benefit from general pain medication and/or disease-modifying OA drug (DMOAD) therapy. Reserved inclusion of these patients in DMOAD trials is advised in the quest for successful OA treatments.Trial registration numberThe study is registered under clinicaltrials.gov nr: NCT03883568.Data are available on reasonable request. In order to gain and govern access to the central IMI-APPROACH databases, tranSMART and XNAT, access has to be approved by the IMI-APPROACH Steering Committee.